Novartis Transderm Scop Comparative Claims With Dramamine Denied By NAD
This article was originally published in The Tan Sheet
Executive Summary
DTC ad claims for Novartis' Rx Transderm Scop declaring superiority to Pharmacia's OTC motion sickness remedy Dramamine are inappropriate due to "very significant differences" between the scopolamine patch's consumer-targeted claims and original FDA-reviewed statements, NAD states Nov. 8.
You may also be interested in...
OTC/Rx Sodium Phosphate Laxative Claim Dispute Referred By NAD
InKline Pharmaceuticals, which sells Rx sodium phosphate tablets, has declined to participate in the NAD self-regulatory forum, maintaining NAD is not the proper authority to review its marketing claims
OTC/Rx Sodium Phosphate Laxative Claim Dispute Referred By NAD
InKline Pharmaceuticals, which sells Rx sodium phosphate tablets, has declined to participate in the NAD self-regulatory forum, maintaining NAD is not the proper authority to review its marketing claims
OTC/Rx Sodium Phosphate Laxative Claim Dispute Referred By NAD
InKline Pharmaceuticals, which sells Rx sodium phosphate tablets, has declined to participate in the NAD self-regulatory forum, maintaining NAD is not the proper authority to review its marketing claims